Detalhe da pesquisa
1.
Cooperation of p53 mutations with other oncogenic alterations in cancer.
Subcell Biochem
; 85: 41-70, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-25201188
2.
The rebel angel: mutant p53 as the driving oncogene in breast cancer.
Carcinogenesis
; 33(11): 2007-17, 2012 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-22822097
3.
The diverse members of the mammalian HSP70 machine show distinct chaperone-like activities.
Biochem J
; 435(1): 127-42, 2011 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-21231916
4.
The molecular network of the proteasome machinery inhibition response is orchestrated by HSP70, revealing vulnerabilities in cancer cells.
Cell Rep
; 40(13): 111428, 2022 09 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-36170818
5.
ATP binding to Hsp90 is sufficient for effective chaperoning of p53 protein.
J Biol Chem
; 285(42): 32020-8, 2010 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-20688913
6.
Parkin Levels Decrease in Fibroblasts With Progranulin (PGRN) Pathogenic Variants and in a Cellular Model of PGRN Deficiency.
Front Mol Neurosci
; 14: 676478, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34054428
7.
The new platinum(IV) derivative LA-12 shows stronger inhibitory effect on Hsp90 function compared to cisplatin.
Mol Cancer
; 9: 147, 2010 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-20550649
8.
A Driver Never Works Alone-Interplay Networks of Mutant p53, MYC, RAS, and Other Universal Oncogenic Drivers in Human Cancer.
Cancers (Basel)
; 12(6)2020 Jun 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32545208
9.
Wild-type p53 oligomerizes more efficiently than p53 hot-spot mutants and overcomes mutant p53 gain-of-function via a "dominant-positive" mechanism.
Oncotarget
; 9(62): 32063-32080, 2018 Aug 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30174797
10.
Mutant p53 tunes the NRF2-dependent antioxidant response to support survival of cancer cells.
Oncotarget
; 9(29): 20508-20523, 2018 Apr 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-29755668
11.
Mutant p53-Nrf2 axis regulates the proteasome machinery in cancer.
Mol Cell Oncol
; 4(1): e1217967, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28197530
12.
Targeting mutant p53 in cancer: a long road to precision therapy.
FEBS J
; 284(6): 837-850, 2017 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-27808469
13.
Identification of a HLA-A*0201-restricted immunogenic epitope from the universal tumor antigen DEPDC1.
Oncoimmunology
; 6(8): e1313371, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28919988
14.
Proteasome machinery is instrumental in a common gain-of-function program of the p53 missense mutants in cancer.
Nat Cell Biol
; 18(8): 897-909, 2016 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-27347849
15.
Mutant p53: One, No One, and One Hundred Thousand.
Front Oncol
; 5: 289, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26734571
16.
Multi-omics reveals global effects of mutant p53 gain-of-function.
Cell Cycle
; 15(22): 3009-3010, 2016 11 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-27458655
17.
Psc3 cohesin of Schizosaccharomyces pombe: cell cycle analysis and identification of three distinct isoforms.
Biol Chem
; 386(7): 613-21, 2005 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-16207082
18.
Hsp90 regulates the activity of wild type p53 under physiological and elevated temperatures.
J Biol Chem
; 279(47): 48846-54, 2004 Nov 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-15358771
19.
Hsp90 chaperones wild-type p53 tumor suppressor protein.
J Biol Chem
; 279(47): 48836-45, 2004 Nov 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-15358769